Eva Johnsson

TL;DR: In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.

TL;DR: There was no suggestion of increased risk for MACE with dapagliflozin compared with control in any of the populations investigated and the results suggest the potential for a beneficial CV effect which is consistent with the multifactorial benefits on CV risk factors associated with sodium–glucose cotransporter-2 (SGLT2) inhibitors.

TL;DR: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects onalbuminuria were mediated through changes in glycated haemoblogin, systolic blood pressure, body weight or eGFR.

TL;DR: Small changes from baseline in mean lipid parameters and reductions in serum uric acid levels were observed in patients taking dapagliflozin, consistent with modest drug-induced diuresis and weight loss.

TL;DR: The long-term effects of dapagliflozin on urinary albumin/creatinine ratio (UACR) in patients with type 2 diabetes and moderate renal impairment were examined to examine whether changes in UACR occur independently of sex and changes in HbA1c, BP, uric acid and estimated GFR (eGFR).